Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Common Equity (2021 - 2026)

HeartSciences filings provide 6 years of Common Equity readings, the most recent being $2.7 million for Q1 2026.

  • On a quarterly basis, Common Equity rose 48.44% to $2.7 million in Q1 2026 year-over-year; TTM through Jan 2026 was $2.7 million, a 48.44% increase, with the full-year FY2025 number at $205171.0, down 97.2% from a year prior.
  • Common Equity hit $2.7 million in Q1 2026 for HeartSciences, down from $4.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $8.6 million in Q1 2024 to a low of -$6.1 million in Q2 2022.
  • Median Common Equity over the past 5 years was $1.8 million (2025), compared with a mean of $1.7 million.
  • Biggest five-year swings in Common Equity: plummeted 252.37% in 2023 and later soared 3447.59% in 2024.
  • HeartSciences' Common Equity stood at $1.1 million in 2022, then plummeted by 252.37% to -$1.6 million in 2023, then surged by 343.48% to $4.0 million in 2024, then increased by 4.13% to $4.2 million in 2025, then crashed by 36.59% to $2.7 million in 2026.
  • The last three reported values for Common Equity were $2.7 million (Q1 2026), $4.2 million (Q4 2025), and $3.1 million (Q3 2025) per Business Quant data.